Cory Berkland, PhD

Cory Berkland, PhD

Primary Academic Title

Professor, Biomedical Engineering, Washington University School of Medicine

Research Interest

Cory Berkland’s lab studies pharmaceuticals and biomaterials with a particular emphasis on molecular design, drug formulation, and transport in the human body. Professor Berkland is a co-founder of Orbis Biosciences (acquired by Adare Pharmaceuticals), Savara Pharmaceuticals (NASDAQ:SVRA), Bond Biosciences, and several other start-ups. Professor Berkland is currently CSO of Bond Biosciences and is an executive and chairman of the board for Kinimmune and Axioforce.

Education

  • 1998: BS, Iowa State University, Ames, IA
  • 2001: MS, Univeristy of Illinois, Urbana, Il
  • 2003: PhD, University of Illinois, Urbana, IL

Training

  • 2014 - 2014: Sabbatical, Sofinnova Ventures, Menlo Park, CA

Selected Research Publications